Most U.S. Adults Lack Hepatitis A or B Immunity Despite Vaccines

A significant portion of the adult population in the United States lacks immunity to both Hepatitis A virus (HAV) and Hepatitis B virus (HBV), according to a recent cross-sectional analysis. This finding is notable because highly effective vaccines for both viruses are readily available, suggesting a gap in vaccination coverage or the waning of immunity over time. The analysis, which utilized data from the National Health and Nutrition Examination Survey (NHANES) spanning 2017-2018, found that only 37.7% of U.S. adults aged 18 and older had serologic evidence of immunity to HAV, while just 35.5% demonstrated immunity to HBV. These figures highlight a substantial public health challenge, as both hepatitis A and B can lead to serious liver conditions, including cirrhosis and liver cancer, and can be transmitted through various means, including contaminated food and water for HAV, and blood and bodily fluids for HBV.

The study's findings are particularly relevant in light of recent recommendations from federal health agencies aimed at improving vaccination rates. In October 2022, the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend routine hepatitis B vaccination for all adults aged 19 through 59 years, regardless of risk factors. Previously, the recommendation was primarily for individuals at increased risk. This expanded recommendation aims to address the persistent burden of HBV infection, which affects an estimated 862,000 people in the U.S. and is a leading cause of liver cancer. The analysis also noted that while HAV immunity was higher among certain demographics, such as those who reported receiving the vaccine, a substantial number of adults remained unprotected. The study did not differentiate between immunity acquired through vaccination and that acquired through prior infection, but the low overall immunity rates suggest that vaccination efforts need to be intensified.

Furthermore, the research underscores the importance of continued surveillance and public health campaigns to educate the public and healthcare providers about the risks associated with hepatitis A and B and the benefits of vaccination. The economic and health-related burdens of these preventable diseases are considerable, encompassing direct medical costs, lost productivity, and the long-term health consequences for infected individuals. The study's authors emphasized that achieving higher immunity levels is crucial for reducing the incidence of these infections and their associated complications. The data from the NHANES survey provides a critical snapshot of the current immunity landscape, serving as a baseline for evaluating the impact of future vaccination strategies and public health interventions. The implications of these findings extend to healthcare policy, resource allocation for vaccination programs, and the ongoing efforts to eliminate viral hepatitis as a public health threat in the United States.